Want to see AIMD full AI Analyst Report?
Ainos (AIMD) AI Stock Analysis
Ainos
(NASDAQ:AIMD)
AIMD scores near the low end of the range, driven primarily by critically weak financials: near-zero revenue, persistent $14M–$15M annual losses, equity collapsing to $3.3M against $11M of debt, and continued $4.5M annual cash burn that creates real going-concern and dilution risk. Technicals reinforce the caution, with the stock trading far below all major moving averages and negative MACD, though extremely oversold RSI and Stochastic readings suggest a possible short-term bounce. Valuation provides no cushion given negative earnings and no dividend. The VELDONA licensing deal and improved governance framework are genuine positives that partially offset the picture, but the potential proceeds are modest relative to the company's funding needs, keeping this a high-risk, speculative situation.
Ainos (AIMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.64M
- Dividend Yield
- ―
- Average Volume (3M)
- 136.48K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 2.25
- Revenue Growth
- -87.73%
- EPS Growth
- 51.12%
- Country
- US
- Employees
- 41
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Biotechnology
Ainos Business Overview & Revenue Model
Company Description
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, whi...
Ainos Financial Statement Overview
Summary
Ainos is in severe financial distress. Revenue has collapsed from $3.5M in 2022 to just $13,600 on a trailing-twelve-month basis, while net losses persist near $14M–$15M annually and gross margins are deeply negative. Stockholders' equity has eroded from $34.6M to $3.3M, debt has climbed to $11M (3.35x debt-to-equity), and return on equity is -217%, pointing to meaningful going-concern risk. Operating and free cash flow remain around -$4.5M, with only a marginal improvement in burn rate, leaving the company dependent on external, likely dilutive, financing.
Income Statement
5Very NegativeBalance Sheet
18Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.60K | 124.16K | 20.73K | 122.11K | 3.52M | 594.56K |
| Gross Profit | -4.76M | -4.68M | -31.87K | -253.73K | 1.41M | 410.38K |
| EBITDA | -8.96M | -9.28M | -9.44M | -8.75M | -9.12M | -1.83M |
| Net Income | -14.45M | -14.77M | -14.86M | -13.77M | -14.01M | -3.89M |
Balance Sheet | ||||||
| Total Assets | 19.56M | 20.87M | 28.82M | 31.84M | 37.11M | 40.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 417.35K | 3.89M | 1.89M | 1.85M | 1.75M |
| Total Debt | 13.81M | 11.00M | 12.00M | 5.96M | 1.27M | 3.62M |
| Total Liabilities | 16.28M | 13.31M | 13.30M | 7.39M | 2.48M | 30.63M |
| Stockholders Equity | 3.28M | 7.56M | 15.52M | 24.45M | 34.63M | 10.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.49M | -4.65M | -5.83M | -4.79M | -3.67M | -1.39M |
| Operating Cash Flow | -4.47M | -4.61M | -5.81M | -4.69M | -3.04M | -1.25M |
| Investing Cash Flow | 23.12K | -2,223 | -125.29K | -101.53K | -630.18K | -180.52K |
| Financing Cash Flow | 4.70M | 1.01M | 8.03M | 4.92M | 3.85M | 3.15M |
Ainos Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Negative. The current price of 0.63 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.24, and below the 200-day MA of 1.60, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 15.66 is Positive, neither overbought nor oversold. The STOCH value of 14.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIMD.
Ainos Risk Analysis
Ainos disclosed 52 risk factors in its most recent earnings report. Ainos reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksAinos Peers Comparison
Overall Rating
SNGX47Neutral
BLRX45Neutral- AIMD41Neutral
CMMB38Underperform
FBLG37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| SNGX | 47Neutral | $7.75M | -0.28 | -181.02% | ― | ― | 66.94% |
| BLRX | 45Neutral | $9.50M | -1.03 | -47.22% | ― | -91.94% | 55.29% |
| AIMD | 41Neutral | $4.64M | -0.25 | -217.50% | ― | -87.73% | 51.12% |
| CMMB | 38Underperform | $8.40M | -1.14 | -70.81% | ― | ― | 56.99% |
| FBLG | 37Underperform | $6.19M | -0.15 | -536.78% | ― | ― | 22.10% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AIMD | Ainos Inc | 0.63 | -2.75 | -81.42% | |
| BLRX | Bioline RX Ltd Sponsored ADR | 1.99 | -1.48 | -42.65% | |
| SNGX | Soligenix Inc | 0.35 | -1.11 | -75.85% | |
| CMMB | Chemomab Therapeutics Ltd. | 1.16 | -1.64 | -58.57% | |
| FBLG | FibroBiologics, Inc. | 0.93 | -6.96 | -88.22% |
Ainos Corporate Events
Ainos Updates Corporate Governance, Formalizes Classified Board
PositiveOn October 14, 2026, Ainos, Inc. adopted amended Corporate Governance Policies that formalize a classified board structure divided into three staggered classes serving three-year terms. The policies clarify how directors are selected, how vacancies a...
Ainos Licenses VELDONA Platform, Shifts Focus to Chemical Intelligence
PositiveOn September 24, 2026, Ainos granted Taiwan-based BioPhoenix a global, exclusive and sublicensable license to develop and commercialize its VELDONA oral interferon alpha technology for Sjögren’s disease and thrombocytopenia, with Ainos bar...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026